ATE482234T1 - Antikörper gegen kdr, deren herstellung und verwendungen - Google Patents

Antikörper gegen kdr, deren herstellung und verwendungen

Info

Publication number
ATE482234T1
ATE482234T1 AT02800666T AT02800666T ATE482234T1 AT E482234 T1 ATE482234 T1 AT E482234T1 AT 02800666 T AT02800666 T AT 02800666T AT 02800666 T AT02800666 T AT 02800666T AT E482234 T1 ATE482234 T1 AT E482234T1
Authority
AT
Austria
Prior art keywords
kdr
disclosed
cdr
antibody
antibody molecules
Prior art date
Application number
AT02800666T
Other languages
English (en)
Inventor
Andrew George Popplewell
Simon Peter Tickle
Karen Zinkewich-Peotti
Robert Kendall Morrison
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE482234T1 publication Critical patent/ATE482234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT02800666T 2001-10-10 2002-10-10 Antikörper gegen kdr, deren herstellung und verwendungen ATE482234T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124317.9A GB0124317D0 (en) 2001-10-10 2001-10-10 Biological products
PCT/GB2002/004619 WO2003031475A2 (en) 2001-10-10 2002-10-10 Antibodies against kdr, their production and uses

Publications (1)

Publication Number Publication Date
ATE482234T1 true ATE482234T1 (de) 2010-10-15

Family

ID=9923562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800666T ATE482234T1 (de) 2001-10-10 2002-10-10 Antikörper gegen kdr, deren herstellung und verwendungen

Country Status (24)

Country Link
US (2) US7452976B2 (de)
EP (1) EP1438340B1 (de)
JP (2) JP4323312B2 (de)
KR (2) KR101018908B1 (de)
CN (1) CN1568331A (de)
AT (1) ATE482234T1 (de)
AU (1) AU2002334135B8 (de)
BR (1) BR0212756A (de)
CA (1) CA2458464A1 (de)
CO (1) CO5580838A2 (de)
DE (1) DE60237778D1 (de)
DK (1) DK1438340T3 (de)
EA (1) EA010970B1 (de)
ES (1) ES2351208T3 (de)
GB (1) GB0124317D0 (de)
HU (1) HUP0401618A3 (de)
IL (1) IL160849A0 (de)
IS (1) IS7173A (de)
MX (1) MXPA04003274A (de)
NO (1) NO20040987L (de)
NZ (1) NZ532758A (de)
PL (1) PL208848B1 (de)
WO (1) WO2003031475A2 (de)
ZA (1) ZA200401910B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MXPA06000798A (es) 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
EP2399936A3 (de) 2004-07-26 2012-02-22 Biogen Idec MA Inc. Anti-CD154-Antikörper
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
US8293233B2 (en) * 2005-03-25 2012-10-23 National Research Council Of Canada Method for isolation of soluble polypeptides
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2125894B1 (de) 2007-03-22 2018-12-19 Biogen MA Inc. Bindungsproteine mit antikörpern, antikörperderivaten und antikörperfragmenten mit spezifischer bindung an cd154 sowie ihre verwendung
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
EP2398498B1 (de) 2009-02-17 2018-09-05 UCB Biopharma SPRL Für humanes ox40 spezifische antikörpermoleküle
CN101531718B (zh) * 2009-04-22 2011-11-02 中国人民解放军南京军区军事医学研究所 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
IN2012DN02401A (de) 2009-09-24 2015-08-21 Ucb Pharma Sa
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
PL2731973T3 (pl) 2011-07-13 2018-04-30 Ucb Biopharma Sprl Bakteryjny szczep gospodarz wykazujący ekspresję dsbc
CA2854153A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
BR112014020697B1 (pt) 2012-02-24 2024-01-09 Alteogen Inc Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
ES2744267T3 (es) 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
EP3612625A4 (de) 2017-04-21 2021-08-18 Mellitus, LLC Verfahren und antikörper für mit diabetes assoziierte anwendungen
EP3853377A4 (de) * 2018-09-19 2022-10-05 Totient, Inc. Mit krebs-assoziierte antikörperzusammensetzungen und verwendungsverfahren
EP3898694A4 (de) * 2018-12-20 2023-02-15 Albert Einstein College of Medicine Antagonistische antikörper gegen den menschlichen immunprüfpunkt ceacam1 (cd66a) und formulierungen, kits und verfahren zur verwendung davon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1009814B1 (de) 1997-06-18 2007-08-29 Merck & Co., Inc. (a New Jersey corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
CA2328893A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
WO2000044777A1 (en) * 1999-01-29 2000-08-03 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof

Also Published As

Publication number Publication date
US7452976B2 (en) 2008-11-18
PL370344A1 (en) 2005-05-16
PL208848B1 (pl) 2011-06-30
KR20040097983A (ko) 2004-11-18
US7842787B2 (en) 2010-11-30
AU2002334135B8 (en) 2009-01-29
DE60237778D1 (de) 2010-11-04
JP2009108086A (ja) 2009-05-21
IS7173A (is) 2004-03-05
ES2351208T3 (es) 2011-02-01
MXPA04003274A (es) 2004-07-08
KR20070116110A (ko) 2007-12-06
DK1438340T3 (da) 2010-11-22
EP1438340A2 (de) 2004-07-21
CN1568331A (zh) 2005-01-19
EA010970B1 (ru) 2008-12-30
HUP0401618A3 (en) 2012-03-28
WO2003031475A3 (en) 2004-03-25
CA2458464A1 (en) 2003-04-17
ZA200401910B (en) 2005-03-09
KR101018908B1 (ko) 2011-03-02
US20050181448A1 (en) 2005-08-18
NZ532758A (en) 2008-04-30
CO5580838A2 (es) 2005-11-30
WO2003031475A2 (en) 2003-04-17
NO20040987L (no) 2004-05-10
EA200400519A1 (ru) 2004-12-30
GB0124317D0 (en) 2001-11-28
IL160849A0 (en) 2004-08-31
US20090269840A1 (en) 2009-10-29
JP2005516590A (ja) 2005-06-09
JP4323312B2 (ja) 2009-09-02
BR0212756A (pt) 2004-11-16
HUP0401618A2 (hu) 2004-11-29
AU2002334135B2 (en) 2009-01-08
WO2003031475A8 (en) 2004-10-14
EP1438340B1 (de) 2010-09-22

Similar Documents

Publication Publication Date Title
ATE482234T1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
LTPA2017044I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
AP2092A (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
ATE482980T1 (de) Antikörper variable region eines monoklonalen antikörpers gegen den humanen tumor nekrose faktor-alpha und dafür kodierendes gen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties